PAION is a specialty pharmaceutical company that develops innovative products for sedation and anesthesia including commercialization.  

 

Learn more About PAION

Remimazolam

PAION's lead compound, Remimazolam, is an ultra-short-acting intravenous sedative and anesthetic that is currently in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam has been investigated in more than 1,000 patients worldwide. 

PAION's Remimazolam

Project update Remimazolam Conference call

15 February 2016, 2 pm

To access the English call, please click here. 

Please chose the appropriate number:

Germany +49 (0) 69 7104 45598
UK +44 (0) 20 3003 2666
US +1 212 999 6659
(other countries: please use the UK number)

Password: "PAION"

news

02/12/2016

US-patent & trademark office grants substance patent for Remimazolam besylate

US-patent & trademark office grants substance patent for...

Read more
02/09/2016

Press Release: PAION discontinues European Remimazolam Phase III Trial in...

PAION discontinues European Remimazolam Phase III Trial in...

Read more
02/09/2016

Ad hoc release: PAION discontinues European Remimazolam Phase III Trial in...

PAION discontinues European Remimazolam Phase III Trial in...

Read more

PAION Chart